William Dowon Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
William Dowon Kim has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Iksung Cho
Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
7 shared publications - Geu-Ru Hong
Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
5 shared publications - Chi Young Shim
Severance Cardiovascular Hospital, Yonsei University College of Medicine
4 shared publications - Jong-Won Ha
Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
4 shared publications - Hasung Kim
Data Science Team, Hanmi Pharm. Co., Ltd, Seoul, Korea
3 shared publications - Ji-Won Hwang
Division of Cardiology, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea
3 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by XMLink in Yonsei Medical Journal
- Vol. 67 (2) , 87-95
Prognosis of Infective Endocarditis According to Clinical Characteristics, Economic Status, and Center Experience
Kim WD, et al. Yonsei Med J. 2025 Dec;66:e114. https://doi.org/10.3349/ymj.2025.0122
- 1 January 2026
- Published by XMLink in Yonsei Medical Journal
- Vol. 67 (2) , 87-95
Open AccessPrognosis of Infective Endocarditis According to Clinical Characteristics, Economic Status, and Center Experience
Kim WD, et al. Yonsei Med J. 2025 Dec;66:e114. https://doi.org/10.3349/ymj.2025.0122
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Korean Medical Science
- Vol. 40 (31) , e183
Trends in Epidemiology, Clinical Characteristics, and Outcomes of Infective Endocarditis: A 16-Year Nationwide Cohort Study in Korea
Ha KE, et al. J Korean Med Sci. 2025 Jun;40:e183. https://doi.org/10.3346/jkms.2025.40.e183
- 1 January 2025
- Published by XMLink in Journal of Korean Medical Science
- Vol. 40 (31) , e183
Open AccessTrends in Epidemiology, Clinical Characteristics, and Outcomes of Infective Endocarditis: A 16-Year Nationwide Cohort Study in Korea
Ha KE, et al. J Korean Med Sci. 2025 Jun;40:e183. https://doi.org/10.3346/jkms.2025.40.e183
- Open Access
- 31 December 2024
- Published by Aerospace Medical Association of Korea in The Korean Journal of Aerospace and Environmental Medicine
- Vol. 34 (4) , 101-107
In-flight Electrocardiography Monitoring in a Pilot During Cross Country Flight
William D. Kim, M.D., Sang-Wook Kim, M.D., Ph.D., Seong-Kyu Cho, M.D., Ju Hyeon Byeon, B.S., GunYoung Lee, Ph.D., WooSeok Hyun, Ph.D., JoungSoon Jang, M.D., Ph.D.. Korean J Aerosp Environ Med 2024;34:101-7. https://doi.org/10.46246/KJAsEM.240023
- 31 December 2024
- Published by Aerospace Medical Association of Korea in The Korean Journal of Aerospace and Environmental Medicine
- Vol. 34 (4) , 101-107
Open AccessIn-flight Electrocardiography Monitoring in a Pilot During Cross Country Flight
William D. Kim, M.D., Sang-Wook Kim, M.D., Ph.D., Seong-Kyu Cho, M.D., Ju Hyeon Byeon, B.S., GunYoung Lee, Ph.D., WooSeok Hyun, Ph.D., JoungSoon Jang, M.D., Ph.D.. Korean J Aerosp Environ Med 2024;34:101-7. https://doi.org/10.46246/KJAsEM.240023
- Open Access
- 1 January 2024
- Published by XMLink in Yonsei Medical Journal
- Vol. 65 (11) , 629-635
Clinical Manifestations and Adverse Cardiovascular Events in Patients with Cardiovascular Symptoms after mRNA Coronavirus Disease 2019 Vaccines
Kim WD, et al. Yonsei Med J. 2024 Nov;65(11):629-635. https://doi.org/10.3349/ymj.2023.0354
- 1 January 2024
- Published by XMLink in Yonsei Medical Journal
- Vol. 65 (11) , 629-635
Open AccessClinical Manifestations and Adverse Cardiovascular Events in Patients with Cardiovascular Symptoms after mRNA Coronavirus Disease 2019 Vaccines
Kim WD, et al. Yonsei Med J. 2024 Nov;65(11):629-635. https://doi.org/10.3349/ymj.2023.0354
- Open Access
- 15 August 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (16) , e029484
Cardiovascular Outcomes of Coronary Computed Tomography Angiography Versus Functional Testing in Suspected Coronary Syndromes: Real‐World Evidence From the Nationwide Cohort
Background: Real‐world evidence for the selection of gatekeeping studies in patients with suspected coronary syndromes is limited. Methods and Results: We identified 27 036 patients who underwent coronary computed tomography angiography (CCTA), single‐photon emission computed tomography, and the treadmill test for suspected coronary syndromes from the Korean National Health Insurance Service–National Sample Cohort between 2006 and 2014. The primary end point was a composite of cardiac death and myocardial infarction, and the secondary end point was a composite of the primary end point and revascularization. During a median follow‐up of 5.4 years, the risk of both primary and secondary end points was significantly higher in the single‐photon emission computed tomography group (hazard ratio [HR], 1.81 [95% CI, 1.34–2.45]; and HR, 1.42 [95% CI, 1.22–1.66]), but significantly lower in the treadmill test group (HR, 0.53 [95% CI, 0.42–0.67]; and HR, 0.69 [95% CI, 0.62–0.76]) compared with the CCTA group. After balancing baseline risk factors, there was no significant difference in the primary end point in those with single‐photon emission computed tomography (HR, 1.11 [95% CI, 0.78–1.57]; P =0.58) or treadmill test (HR, 0.84 [95% CI, 0.65–1.08]; P =0.18) groups, compared with the CCTA group. The event rate of the secondary end point was significantly lower in the treadmill test group than in the CCTA group (HR, 0.87 [95% CI, 0.78–0.96]; P =0.008). Conclusions: Compared with functional testing, initial CCTA was not associated with a lower rate of cardiac death or myocardial infarction when used as an initial diagnostic test for patients with suspected coronary syndromes.
- 15 August 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (16) , e029484
Open AccessCardiovascular Outcomes of Coronary Computed Tomography Angiography Versus Functional Testing in Suspected Coronary Syndromes: Real‐World Evidence From the Nationwide Cohort
Background: Real‐world evidence for the selection of gatekeeping studies in patients with suspected coronary syndromes is limited. Methods and Results: We identified 27 036 patients who underwent coronary computed tomography angiography (CCTA), single‐photon emission computed tomography, and the treadmill test for suspected coronary syndromes from the Korean National Health Insurance Service–National Sample Cohort between 2006 and 2014. The primary end point was a composite of cardiac death and myocardial infarction, and the secondary end point was a composite of the primary end point and revascularization. During a median follow‐up of 5.4 years, the risk of both primary and secondary end points was significantly higher in the single‐photon emission computed tomography group (hazard ratio [HR], 1.81 [95% CI, 1.34–2.45]; and HR, 1.42 [95% CI, 1.22–1.66]), but significantly lower in the treadmill test group (HR, 0.53 [95% CI, 0.42–0.67]; and HR, 0.69 [95% CI, 0.62–0.76]) compared with the CCTA group. After balancing baseline risk factors, there was no significant difference in the primary end point in those with single‐photon emission computed tomography (HR, 1.11 [95% CI, 0.78–1.57]; P =0.58) or treadmill test (HR, 0.84 [95% CI, 0.65–1.08]; P =0.18) groups, compared with the CCTA group. The event rate of the secondary end point was significantly lower in the treadmill test group than in the CCTA group (HR, 0.87 [95% CI, 0.78–0.96]; P =0.008). Conclusions: Compared with functional testing, initial CCTA was not associated with a lower rate of cardiac death or myocardial infarction when used as an initial diagnostic test for patients with suspected coronary syndromes.
- Open Access
- 15 September 2022
- Published by XMLink in Korean Circulation Journal
- Vol. 52 (11) , 814-825
Nationwide Trends of Gatekeeper to Invasive Coronary Angiography in Suspected Coronary Artery Disease
Korean Circulation Journal 대한심장학회지 순환기 Cha MJ, et al. Korean Circ J. 2022 Sep;52:e91. https://doi.org/10.4070/kcj.2022.0110
- 15 September 2022
- Published by XMLink in Korean Circulation Journal
- Vol. 52 (11) , 814-825
Open AccessNationwide Trends of Gatekeeper to Invasive Coronary Angiography in Suspected Coronary Artery Disease
Korean Circulation Journal 대한심장학회지 순환기 Cha MJ, et al. Korean Circ J. 2022 Sep;52:e91. https://doi.org/10.4070/kcj.2022.0110
- Open Access
Cancer Therapy-Related Cardiac Dysfunction in Patients Treated with a Combination of an Immune Checkpoint Inhibitor and Doxorubicin
Backgrounds: There are scarce data on whether immune checkpoint inhibitors (ICIs) increase the risk of cardiac dysfunction when used with cardiotoxic agents. Thus, we evaluated cardiac dysfunction in patients with sarcoma receiving doxorubicin with or without ICI using echocardiography and left ventricular global longitudinal strain (LVGLS). Methods: A total of 95 patients were included in this study. Echocardiography and LVGLS were evaluated at baseline and follow-up (at 3 and 6 months of chemotherapy) and compared with the doxorubicin (Dox; n = 73) and concomitant ICI with doxorubicin (Dox-ICI; n = 22) groups. Cancer therapy-related cardiac dysfunction (CTRCD) was defined as a left ventricular ejection fraction (LVEF) drop of >10% and LVEF of 10%, LVEF of ≥50%, and LVGLS relative reduction of >15% (probable CTRCD) at six months. Results: There were no significant differences in age, cumulative dose of doxorubicin, and cardiovascular risk factors between the two groups. At baseline, the LVEF was similar in the Dox and Dox-ICI groups (p = 0.493). In the Dox group, LVEF decreased to 59 ± 6% (Δ −7 ± 1.3%, p < 0.001) and LVGLS decreased from −17.3 ± 3.2% to −15.4 ± 3.2% (Δ −10.1 ± −1.9%, p < 0.001) at six months. In the Dox-ICI group, LVEF decreased to 55 ± 9% (Δ −9 ± 2.1%, p < 0.001), along with a significant decrease in LVGLS (from −18.6 ± 1.9% to −15.3 ± 3.6%, Δ −12.4 ± −2.4%, p < 0.001). Over a median follow-up of 192 days, there were no cases with clinical manifestations of fulminant myocarditis. In the Dox group, definite and probable CTRCD were observed in seven (10.1%) and five (7.4%) patients, respectively. In the Dox-ICI group, definite and probable CTRCD were observed in four (19%) and four (19%) patients, respectively. The total number of patients who developed CTRCD was significantly higher in the Dox-ICI group than in the Dox group (38.1% vs. 17.4%, p = 0.042). Serum troponin-T level was significantly higher in the Dox-ICI group than in the Dox group (53.3 vs. 27.5 pg/mL, p = 0.023). Conclusions: ICIs may increase the risk of CTRCD when used with cardiotoxic agents. CTRCD should be monitored in patients treated with ICIs by cardiac biomarkers and echocardiography, including LV-GLS.
Open AccessCancer Therapy-Related Cardiac Dysfunction in Patients Treated with a Combination of an Immune Checkpoint Inhibitor and Doxorubicin
Backgrounds: There are scarce data on whether immune checkpoint inhibitors (ICIs) increase the risk of cardiac dysfunction when used with cardiotoxic agents. Thus, we evaluated cardiac dysfunction in patients with sarcoma receiving doxorubicin with or without ICI using echocardiography and left ventricular global longitudinal strain (LVGLS). Methods: A total of 95 patients were included in this study. Echocardiography and LVGLS were evaluated at baseline and follow-up (at 3 and 6 months of chemotherapy) and compared with the doxorubicin (Dox; n = 73) and concomitant ICI with doxorubicin (Dox-ICI; n = 22) groups. Cancer therapy-related cardiac dysfunction (CTRCD) was defined as a left ventricular ejection fraction (LVEF) drop of >10% and LVEF of 10%, LVEF of ≥50%, and LVGLS relative reduction of >15% (probable CTRCD) at six months. Results: There were no significant differences in age, cumulative dose of doxorubicin, and cardiovascular risk factors between the two groups. At baseline, the LVEF was similar in the Dox and Dox-ICI groups (p = 0.493). In the Dox group, LVEF decreased to 59 ± 6% (Δ −7 ± 1.3%, p < 0.001) and LVGLS decreased from −17.3 ± 3.2% to −15.4 ± 3.2% (Δ −10.1 ± −1.9%, p < 0.001) at six months. In the Dox-ICI group, LVEF decreased to 55 ± 9% (Δ −9 ± 2.1%, p < 0.001), along with a significant decrease in LVGLS (from −18.6 ± 1.9% to −15.3 ± 3.6%, Δ −12.4 ± −2.4%, p < 0.001). Over a median follow-up of 192 days, there were no cases with clinical manifestations of fulminant myocarditis. In the Dox group, definite and probable CTRCD were observed in seven (10.1%) and five (7.4%) patients, respectively. In the Dox-ICI group, definite and probable CTRCD were observed in four (19%) and four (19%) patients, respectively. The total number of patients who developed CTRCD was significantly higher in the Dox-ICI group than in the Dox group (38.1% vs. 17.4%, p = 0.042). Serum troponin-T level was significantly higher in the Dox-ICI group than in the Dox group (53.3 vs. 27.5 pg/mL, p = 0.023). Conclusions: ICIs may increase the risk of CTRCD when used with cardiotoxic agents. CTRCD should be monitored in patients treated with ICIs by cardiac biomarkers and echocardiography, including LV-GLS.
- Open Access
- 1 January 2020
- Published by The Korean Society of Cardiology in Korean Circulation Journal
- Vol. 50 (7) , 610-612
Early Testing and Prompt Initiation of Proper Treatment: a Clever Strategy to Fight with Tuberculosis Pericarditis
Korean Circulation Journal 대한심장학회지 순환기 Cho I, et al. Korean Circ J. 2019 Aug;50:e96. https://doi.org/10.4070/kcj.2020.0179
- 1 January 2020
- Published by The Korean Society of Cardiology in Korean Circulation Journal
- Vol. 50 (7) , 610-612
Open AccessEarly Testing and Prompt Initiation of Proper Treatment: a Clever Strategy to Fight with Tuberculosis Pericarditis
Korean Circulation Journal 대한심장학회지 순환기 Cho I, et al. Korean Circ J. 2019 Aug;50:e96. https://doi.org/10.4070/kcj.2020.0179